Pres­i­dent Don­ald Trump on Fri­day an­nounced that all 50 states, Wash­ing­ton, DC, and Puer­to Ri­co will par­tic­i­pate in a new drug pric­ing mod­el un­der which...

The "most fa­vored na­tion" drug pric­ing deals that Pfiz­er and Eli Lil­ly signed with the Trump ad­min­is­tra­tion sug­gest the com­pa­nies will give the gov­ern­ment a...

Six UK gov­ern­ment com­mit­tees have called for an in­ves­ti­ga­tion in­to the cost of the UK’s phar­ma­ceu­ti­cal trade deal with the US.

The let­ter, pub­lished...

Amer­i­can trade of­fi­cials on Tues­day heard tes­ti­mo­ny for and against an in­ves­ti­ga­tion linked to Ger­many's de­clin­ing pay­ments for drugs, as EU-based phar­ma ex­ec­u­tives are push­ing...

The US De­part­ment of De­fense is de­fend­ing its de­ci­sion to list WuXi AppTec as a Chi­nese mil­i­tary com­pa­ny, a des­ig­na­tion that may re­strict the man­u­fac­tur­er's...

A new gov­ern­ment pro­gram that will push the bound­aries of AI in med­i­cine could trans­form how the US cares for pa­tients with heart fail­ure and...

Be­fore its ad­vi­so­ry com­mit­tee meet­ings, the FDA typ­i­cal­ly re­leas­es brief­ing doc­u­ments to pro­vide pos­i­tive or neg­a­tive per­spec­tive on whether a treat­ment works or is safe...